Arena Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Arena Pharmaceuticals generated cash of -$452,016,000, which is less than the previous year. Cash used in financing activities reached the amount of $135,407,000 last year. Net change in cash is therefore $5,028,000.
Cash Flow
| 2012 | -44.04M | -2.17M | 144.10M |
|---|---|---|---|
| 2013 | 72.8M | -8.66M | 1.65M |
| 2014 | -101.39M | 40.90M | 3.16M |
| 2015 | -98.11M | -8.15M | 101.13M |
| 2016 | -62.13M | -750K | -2.28M |
| 2017 | -66.64M | -112.35M | 245.28M |
| 2018 | -132.21M | -254.67M | 385.03M |
| 2019 | 568.69M | -497.94M | 9.86M |
| 2020 | -353.09M | -21.40M | 350.60M |
| 2021 | -452.01M | 321.40M | 135.40M |
ARNA Cash Flow Statement (2012 – 2021)
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 219.77M | 243.5M | 161.9M | 159.7M | 90.71M | 156.18M | 163.20M | 221.87M | 156.09M | 57.63M |
Operating activities | ||||||||||
Net income | -616.43M | -404.73M | 397.55M | -29.39M | -91.40M | -22.51M | -107.97M | -60.50M | -19.43M | -85.47M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 3.87M | 3.85M | 3.23M | 3.75M | 4.27M | 9.35M | 10.04M | 9.16M | 8.20M | 9.74M |
Stock-based compensation expense | 70.37M | 59.92M | 53.04M | 19.54M | 7.85M | 11.11M | 14.46M | 13.50M | 9.02M | 5.07M |
| Deferred income tax benefit | 70.37M | 59.92M | 53.04M | 19.54M | 7.85M | 11.11M | 14.46M | 13.50M | 9.02M | 5.07M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 1.10M | 344K | 3.43M | -2.76M | 10.78M | -15.90M | -1.42M | 6.40M | -4.47M | -5.26M |
Inventories | 0 | -12.60M | 0 | -14.90M | 585K | 3.19M | 1.85M | 870K | -6.06M | -5.87M |
Accounts payable | 5.61M | 11.85M | 0 | 10.87M | 1.80M | -103K | -16.97M | 13.24M | 19.57M | 276K |
Cash generated by operating activities | -452.01M | -353.09M | 568.69M | -132.21M | -66.64M | -62.13M | -98.11M | -101.39M | 72.8M | -44.04M |
Investing activities | ||||||||||
Purchases Of Investments | -612.21M | -1.03B | -1.46B | -364.53M | -112.61M | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -70.98M | -820K | -4.81M | -692K | -113K | -950K | -10.99M | -8.90M | -9.16M | -1.77M |
Acquisitions Net | 0 | 0 | 0 | 0 | -406K | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 321.40M | -21.40M | -497.94M | -254.67M | -112.35M | -750K | -8.15M | 40.90M | -8.66M | -2.17M |
Financing activities | ||||||||||
Common Stock Issued | 98.43M | 354.42M | 13.14M | 389.03M | 248.80M | 370K | 103.62M | 5.22M | 3.31M | 151.21M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -4.40M | -3.81M | 0 | -4M | 0 | -2.97M | 0 | -2.05M | -1.66M | -23.57M |
Cash used in financing activities | 135.40M | 350.60M | 9.86M | 385.03M | 245.28M | -2.28M | 101.13M | 3.16M | 1.65M | 144.10M |
Net Change In Cash | 5.02M | -23.73M | 81.6M | 2.2M | 68.12M | -65.47M | -7.02M | -58.66M | 65.78M | 98.45M |
Cash at end of period | 224.79M | 219.77M | 243.5M | 161.9M | 158.83M | 90.71M | 156.18M | 163.20M | 221.87M | 156.09M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |